The FDA’s data on mifepristone can’t be trusted — here’s why

For the review to withstand the necessary scrutiny it will face upon publication, the FDA must prioritize robust, real-world data sources.

The Hill

18 Jun 2026 1 hour ago 1 min read

The FDA’s data on mifepristone can’t be trusted — here’s why

The Hill — 18 June 2026

Text:

2 0 0

🎙️ AI Podcast — Two-Host Discussion

The FDA’s data on mifepristone can’t be trusted — here’s why

Kokoro TTS · ~5 min episode · American English voices

Choose voices for Host A and Host B. Changes take effect on next play.

Host A 🟥

Host B 🟦

For the review to withstand the necessary scrutiny it will face upon publication, the FDA must prioritize robust, real-world data sources.

This report comes from The Hill. The story centres on The FDA’s data on mifepristone can’t be trusted — here’s why. Full coverage and background context is available at the original source. Readers seeking more detail on this developing topic are encouraged to follow updates from The Hill and related outlets covering this beat.